NASDAQ:CRVS   Corvus Pharmaceuticals, Inc.
Leading diagonal completed, now in wave 2.

Out of all stocks biotech is probably the most susceptible to wrong Elliott wave counts because they are volatile due to news and trial results having a heavy influence on the stock. Nevertheless, this is a view of what the future may hold.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。